Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Express Scripts
Dow
Colorcon
Moodys

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

NEURONTIN Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Neurontin, and what generic alternatives are available?

Neurontin is a drug marketed by Pfizer Pharms and Parke Davis and is included in three NDAs. There is one patent protecting this drug.

This drug has fifty-two patent family members in forty-six countries.

The generic ingredient in NEURONTIN is gabapentin. There are twenty-nine drug master file entries for this compound. Eighty-two suppliers are listed for this compound. Additional details are available on the gabapentin profile page.

Drug patent expirations by year for NEURONTIN
Drug Prices for NEURONTIN

See drug prices for NEURONTIN

Drug Sales Revenue Trends for NEURONTIN

See drug sales revenues for NEURONTIN

Recent Clinical Trials for NEURONTIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dow University of Health SciencesPhase 4
Francisco Unda SolanoPhase 4
Emory UniversityPhase 3

See all NEURONTIN clinical trials

Recent Litigation for NEURONTIN

Identify potential future generic entrants

District Court Litigation
Case NameDate
DEPOMED, INC. v. ACTAVIS ELIZABETH LLC2012-03-02
Warner-Lambert Co v. Apotex Corp
PFIZER INC. v. EON LABS MANUFACTURI

See all NEURONTIN litigation

Pharmacology for NEURONTIN
Synonyms for NEURONTIN
(1-Aminomethyl-cyclohexyl)-acetic acid
[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
1-(Aminomethyl)-cyclohexaneacetic acid
1-(Aminomethyl)-cyclohexaneacetic acid; Neurontin
1-(aminomethyl)cyclohexanacetic acid
1-(Aminomethyl)cyclohexaneacetic acid
1-(Aminomethyl)cyclohexaneaceticAcid
1-(aminomethyl)cyclohexyl-acetic Acid
1-aminomethyl cyclohexaneacetic acid
1-aminomethyl-1-cyclohexane-acetic acid
1-Aminomethyl-1cyclohexane-acetic acid
2-(1-(aminomethyl)cyclohexyl)acetic acid
2-[(aminomethyl)cyclohexyl]acetic acid
2-[1-(aminomethyl)cyclohexyl]acetic acid
42G963
60142-96-3
6CW7F3G59X
AB0068842
AB07485
AB1000455
AC-1485
AC1L1FYE
AC1Q53PH
Aclonium
ACT03340
AJ-08236
AKOS000280865
AM20070538
AN-14914
ANW-43124
BBL010794
BCP25698
BDBM50080153
BIDD:GT0656
BPBio1_000993
BR-35803
BRN 2359739
BSPBio_000901
C07018
C9H17NO2
CAS-60142-96-3
CCG-204671
CCRIS 7210
CHEBI:42797
CHEMBL940
CI 945
CI-945
CPD000058311
CS-1545
CTK3J2213
Cyclohexaneacetic acid, 1-(aminomethyl)-
D00332
DB00996
DDS-2003
DM-1796
DM-5689
DSSTox_CID_74
DSSTox_GSID_20074
DSSTox_RID_75350
DTXSID0020074
EINECS 262-076-3
EN300-52516
EU-0100582
Fanatrex
FT-0626586
G-154
G0318
Gabapen
gabapentin
Gabapentin (JAN/USAN/INN)
gabapentin (Neurontin)
Gabapentin [USAN:INN:BAN]
Gabapentin [USAN:USP:INN:BAN]
Gabapentin GR
Gabapentin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
Gabapentin solution, 10 mg/mL in methanol, ampule of 1 mL, certified reference material
Gabapentin-ER
Gabapentin, European Pharmacopoeia (EP) Reference Standard
Gabapentin, Pharmaceutical Secondary Standard; Certified Reference Material
Gabapentin, solid
Gabapentin, United States Pharmacopeia (USP) Reference Standard
GABAPENTIN; NEURONTIN
gabapentina
Gabapentine
Gabapentine [INN-French]
gabapentinium
Gabapentino
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentinum
Gabapentinum [INN-Latin]
Gabapetin
GBN
Go 3450
GOE 2450
GOE 3450
GOE 3450; CI 945; GO 3450
Goe-3450
Gralise
Gralise (TN)
GTPL5483
HMS1570N03
HMS2089J03
HMS2097N03
HMS2236O03
HMS3261F06
HMS3650A20
HMS3714N03
HSDB 7364
HY-A0057
I06-0677
KS-00000AF6
KS-1064
KSC492E1H
L000733
Lopac-G-154
Lopac0_000582
LP00582
LS-7194
M-2788
MCULE-5392848565
MFCD00865286
MFCD00865286 (98%)
MLS000069358
MolPort-000-883-862
NCGC00015466-01
NCGC00015466-02
NCGC00015466-03
NCGC00015466-04
NCGC00015466-05
NCGC00015466-06
NCGC00015466-07
NCGC00015466-08
NCGC00015466-09
NCGC00015466-11
NCGC00016891-01
NCGC00021545-02
NCGC00021545-04
NCGC00021545-05
NCGC00261267-01
Neuontin
Neurentin
Neurontin (TN)
Novo-Gabapentin
Novo-Gabapentine
NSC-742194
NSC742194
Prestwick_151
Prestwick0_000861
Prestwick1_000861
Prestwick2_000861
Prestwick3_000861
RTR-020802
s2133
SAM002548985
SAM002589946
SBB066157
SBI-0206904.P001
SC-12130
SCHEMBL8343
Sefelsa
Serada
SMR000058311
SPBio_002822
SR-01000000019
SR-01000000019-11
SR-01000000019-2
SR-01000000019-6
ST2410212
STK598009
SY005403
Therapentin-90
TL8003814
Tocris-0806
Tox21_110157
Tox21_110157_1
Tox21_500582
TR-020802
TRA0097671
UGJMXCAKCUNAIE-UHFFFAOYSA-N
UNII-6CW7F3G59X
Vultin
Z1258578343
ZINC4949
Paragraph IV (Patent) Challenges for NEURONTIN
Tradename Dosage Ingredient NDA Submissiondate
NEURONTIN CAPSULE;ORAL gabapentin 020235
NEURONTIN TABLET;ORAL gabapentin 020882
NEURONTIN SOLUTION;ORAL gabapentin 021129

US Patents and Regulatory Information for NEURONTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-001 Dec 30, 1993 AB RX Yes No   Start Trial   Start Trial   Start Trial
Parke Davis NEURONTIN gabapentin SOLUTION;ORAL 021129-001 Mar 2, 2000 AA RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-002 Dec 30, 1993 AB RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-003 Dec 30, 1993 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Pfizer Pharms NEURONTIN gabapentin TABLET;ORAL 020882-002 Oct 9, 1998 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NEURONTIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Parke Davis NEURONTIN gabapentin SOLUTION;ORAL 021129-001 Mar 2, 2000   Start Trial   Start Trial
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-003 Dec 30, 1993   Start Trial   Start Trial
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-003 Dec 30, 1993   Start Trial   Start Trial
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-001 Dec 30, 1993   Start Trial   Start Trial
Pfizer Pharms NEURONTIN gabapentin TABLET;ORAL 020882-002 Oct 9, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Baxter
Medtronic
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.